RU95109929A - Сульфонамидные производные, фармацевтическая композиция и способ лечения млекопитающих - Google Patents
Сульфонамидные производные, фармацевтическая композиция и способ лечения млекопитающихInfo
- Publication number
- RU95109929A RU95109929A RU95109929/04A RU95109929A RU95109929A RU 95109929 A RU95109929 A RU 95109929A RU 95109929/04 A RU95109929/04 A RU 95109929/04A RU 95109929 A RU95109929 A RU 95109929A RU 95109929 A RU95109929 A RU 95109929A
- Authority
- RU
- Russia
- Prior art keywords
- compounds
- methods
- sulfoamide
- mammals
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/09—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by at least two halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96433792A | 1992-10-21 | 1992-10-21 | |
| US07/964,337 | 1992-10-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU95109929A true RU95109929A (ru) | 1997-03-20 |
Family
ID=25508435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU95109929/04A RU95109929A (ru) | 1992-10-21 | 1993-09-30 | Сульфонамидные производные, фармацевтическая композиция и способ лечения млекопитающих |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5641789A (enExample) |
| EP (1) | EP0665842A1 (enExample) |
| JP (1) | JPH07508534A (enExample) |
| KR (1) | KR950704309A (enExample) |
| CN (1) | CN1090282A (enExample) |
| AP (1) | AP9300578A0 (enExample) |
| AU (1) | AU5536794A (enExample) |
| BR (1) | BR9307277A (enExample) |
| CA (1) | CA2146261A1 (enExample) |
| CZ (1) | CZ100095A3 (enExample) |
| FI (1) | FI934625A7 (enExample) |
| HR (1) | HRP931297A2 (enExample) |
| HU (1) | HUT68323A (enExample) |
| IL (1) | IL107294A0 (enExample) |
| MA (1) | MA23009A1 (enExample) |
| MX (1) | MX9306528A (enExample) |
| NO (1) | NO303224B1 (enExample) |
| PL (1) | PL308474A1 (enExample) |
| RU (1) | RU95109929A (enExample) |
| SI (1) | SI9300554A (enExample) |
| TW (1) | TW265335B (enExample) |
| WO (1) | WO1994008996A1 (enExample) |
| ZA (1) | ZA937782B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5539128A (en) * | 1994-11-30 | 1996-07-23 | Pfizer Inc. | Processes and intermediates for preparing cis(+)3-[4,6-dihydroxy chroman-3-ylmethyl]-4-methoxyaniline |
| US6075016A (en) | 1996-04-10 | 2000-06-13 | Euro-Celtique S.A. | 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity |
| US6096906A (en) * | 1996-09-16 | 2000-08-01 | Pfizer Inc. | Processes for preparing substituted chromanol derivatives |
| ZA981080B (en) | 1997-02-11 | 1998-08-12 | Warner Lambert Co | Bicyclic inhibitors of protein farnesyl transferase |
| GB9800039D0 (en) * | 1998-01-02 | 1998-03-04 | Univ Cardiff | Benzyl and benzylidene tetralins and derivatives |
| RU2182004C1 (ru) * | 2001-02-22 | 2002-05-10 | Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" | Лекарственный препарат для парентерального применения |
| KR100768024B1 (ko) * | 2001-04-10 | 2007-10-18 | 다카라 바이오 가부시키가이샤 | 치료제 |
| US7851486B2 (en) * | 2002-10-17 | 2010-12-14 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment |
| US7507531B2 (en) * | 2002-10-17 | 2009-03-24 | Decode Genetics Chf. | Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction |
| JP2006508180A (ja) * | 2002-10-17 | 2006-03-09 | デコード ジェネティクス イーエッチエフ． | 心筋梗塞に対する感受性遺伝子；治療の方法 |
| US20060019269A1 (en) * | 2002-10-17 | 2006-01-26 | Decode Genetics, Inc. | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment |
| US20080293750A1 (en) * | 2002-10-17 | 2008-11-27 | Anna Helgadottir | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment |
| US20050272051A1 (en) * | 2003-09-17 | 2005-12-08 | Decode Genetics Ehf. | Methods of preventing or treating recurrence of myocardial infarction |
| US8158362B2 (en) * | 2005-03-30 | 2012-04-17 | Decode Genetics Ehf. | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype |
| US20100216863A1 (en) * | 2004-01-30 | 2010-08-26 | Decode Genetics Ehf. | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment |
| US20060210514A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Skin protection and moisturizing compositions and method of making the same |
| CN119912349B (zh) * | 2023-10-31 | 2025-11-21 | 中国石油天然气股份有限公司 | 一种可降解凝胶用交联剂、制备方法及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5059609A (en) * | 1987-10-19 | 1991-10-22 | Pfizer Inc. | Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases |
| US5395842A (en) * | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
| WO1990015801A1 (en) * | 1989-06-22 | 1990-12-27 | Pfizer Inc. | Substituted sulfonamides and related compounds in the treatment of asthma, arthritis and related diseases |
-
1993
- 1993-09-30 CZ CZ951000A patent/CZ100095A3/cs unknown
- 1993-09-30 EP EP94900348A patent/EP0665842A1/en not_active Ceased
- 1993-09-30 US US08/416,681 patent/US5641789A/en not_active Expired - Fee Related
- 1993-09-30 KR KR1019950701525A patent/KR950704309A/ko not_active Ceased
- 1993-09-30 WO PCT/US1993/009171 patent/WO1994008996A1/en not_active Ceased
- 1993-09-30 BR BR9307277A patent/BR9307277A/pt not_active Application Discontinuation
- 1993-09-30 AU AU55367/94A patent/AU5536794A/en not_active Abandoned
- 1993-09-30 CA CA002146261A patent/CA2146261A1/en not_active Abandoned
- 1993-09-30 RU RU95109929/04A patent/RU95109929A/ru unknown
- 1993-09-30 JP JP6510027A patent/JPH07508534A/ja active Pending
- 1993-09-30 PL PL93308474A patent/PL308474A1/xx unknown
- 1993-10-06 TW TW082108282A patent/TW265335B/zh active
- 1993-10-07 AP APAP/P/1993/000578A patent/AP9300578A0/en unknown
- 1993-10-14 IL IL107294A patent/IL107294A0/xx unknown
- 1993-10-18 HR HR07/964,337A patent/HRP931297A2/xx not_active Application Discontinuation
- 1993-10-20 MA MA23314A patent/MA23009A1/fr unknown
- 1993-10-20 ZA ZA937782A patent/ZA937782B/xx unknown
- 1993-10-20 HU HU9302969A patent/HUT68323A/hu unknown
- 1993-10-20 CN CN93119221A patent/CN1090282A/zh active Pending
- 1993-10-20 SI SI9300554A patent/SI9300554A/sl unknown
- 1993-10-20 MX MX9306528A patent/MX9306528A/es unknown
- 1993-10-20 FI FI934625A patent/FI934625A7/fi not_active Application Discontinuation
-
1995
- 1995-04-20 NO NO951506A patent/NO303224B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO951506L (no) | 1995-04-20 |
| MA23009A1 (fr) | 1994-07-01 |
| HRP931297A2 (en) | 1996-08-31 |
| FI934625A0 (fi) | 1993-10-20 |
| HU9302969D0 (en) | 1993-12-28 |
| AP9300578A0 (en) | 1995-04-07 |
| EP0665842A1 (en) | 1995-08-09 |
| SI9300554A (en) | 1995-04-30 |
| PL308474A1 (en) | 1995-08-07 |
| CA2146261A1 (en) | 1994-04-28 |
| WO1994008996A1 (en) | 1994-04-28 |
| MX9306528A (es) | 1994-06-30 |
| US5641789A (en) | 1997-06-24 |
| CZ100095A3 (en) | 1995-11-15 |
| IL107294A0 (en) | 1994-01-25 |
| ZA937782B (en) | 1995-04-20 |
| FI934625L (fi) | 1994-04-22 |
| CN1090282A (zh) | 1994-08-03 |
| NO951506D0 (no) | 1995-04-20 |
| HUT68323A (en) | 1995-06-28 |
| TW265335B (enExample) | 1995-12-11 |
| AU5536794A (en) | 1994-05-09 |
| NO303224B1 (no) | 1998-06-15 |
| KR950704309A (ko) | 1995-11-17 |
| FI934625A7 (fi) | 1994-04-22 |
| BR9307277A (pt) | 1999-05-11 |
| JPH07508534A (ja) | 1995-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU95109929A (ru) | Сульфонамидные производные, фармацевтическая композиция и способ лечения млекопитающих | |
| RU93058555A (ru) | Производные хинуклидина, способ их получения, фармацевтическая композиция, способ лечения или профилактики | |
| LU91145I2 (fr) | FIROCOXIB facultativement sous forme d'un sel pharmaceutiquement acceptable (PREVICOX). | |
| TNSN99191A1 (fr) | Derives d'adenine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| PT723540E (pt) | Compostos triciclicos de amida e ureia uteis para inibicao da funcao da g-proteina e para o tratamento de doencas proliferativas. | |
| NO174772C (no) | Analogifremgangsmåte ved fremstilling av terapeutisk aktive piperazinylderivater | |
| FR2401159A1 (fr) | Derives de 3-(1h-tetrazol-5-yl)-4h-pyrido(1,2-a)pyrimidine-4-one, leur procede de preparation et leur activite therapeutique | |
| EA200100553A1 (ru) | Замещенные бициклические производные, полезные в качестве противораковых агентов | |
| FI925342L (fi) | Menetelmä terapeuttisesti aktiivisen (+)- -(2,3-dimetoksifenyyli)-1-/2-(4-fluorifenyyli)etyyli/-4-piperidiinimetanolin valmistamiseksi | |
| ZA947969B (en) | Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases | |
| RU94020400A (ru) | Производные индола, способ их получения, фармацевтическая композиция, способ лечения головной боли | |
| CA2386799A1 (en) | Fused cycloheptane and fused azacycloheptane compounds and their as integrin receptor antagonists | |
| HUT61555A (en) | Process for producing 2,8-dioxa-bicyclo/3.2.1/octane derivatives and pharmaceutical compositions comprising same | |
| EP0700911B1 (en) | Imidazole derivatives having anti-HIV activity | |
| HU911301D0 (en) | Process for producing 2,9-disubstituted 4h-pyrido(1,2a)-pyrimidine derivatives and pharmaceutical preparatives containing these compounds as active substance | |
| RU92004509A (ru) | Замещенные фенилфенольные соединения, фармацевтическая композиция, способ получения | |
| RU94036749A (ru) | Замещенные 1-нафтилпиразол-3-карбоксамиды, способ их получения, содержащие их фармацевтические композиции и промежуточные соединения синтеза | |
| EP0227241A3 (en) | Medicinal indole and indazole keto sulphone derivatives | |
| RU95113434A (ru) | Диметилбензофураны и диметилбензопираны, их применение в качестве 5-нт*003-антагонистов, способы их получения, фармацевтическая композиция | |
| MA21902A1 (fr) | Procede pour la preparation de peptitides hemoregulateurs et des compositions pharmaceutiques les comtenant . | |
| RU94030470A (ru) | Производные 1-(арилалкиламиноалкил)имидазола, способ их получения, фармацевтическая композиция и способ лечения | |
| FI900365A0 (fi) | Menetelmä terapeuttisesti käyttökelpoisten 3-fenyyli-5,6-dihydrobents/C/akridiini-7-karboksyylihappojohdannnaisten valmistamiseksi | |
| BE883686A (fr) | Derives de la paromomycine, procede pour les preparer et leur usage comme medicament | |
| ATE152708T1 (de) | (1,2n) und (3,2n)-karbozyklische-2-amino- tetralinderivate | |
| RU94038063A (ru) | 3-фенилуреидо-азепин-2-оны и -бензазепин-2-оны, способы их получения, промежуточные соединения, фармацевтические композиции и способы лечения |